| __timestamp | Dynavax Technologies Corporation | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 11606000000 |
| Thursday, January 1, 2015 | 22180000 | 10313000000 |
| Friday, January 1, 2016 | 37257000 | 9762000000 |
| Sunday, January 1, 2017 | 27367000 | 9830000000 |
| Monday, January 1, 2018 | 64770000 | 10102000000 |
| Tuesday, January 1, 2019 | 74986000 | 10615000000 |
| Wednesday, January 1, 2020 | 79256000 | 8955000000 |
| Friday, January 1, 2021 | 100156000 | 9634000000 |
| Saturday, January 1, 2022 | 131408000 | 10042000000 |
| Sunday, January 1, 2023 | 152946000 | 10504000000 |
Unleashing insights
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Merck & Co., Inc. and Dynavax Technologies Corporation have shown contrasting trends in their SG&A expenses. From 2014 to 2023, Merck's SG&A expenses have remained relatively stable, averaging around $10 billion annually, with a slight dip in 2020. In contrast, Dynavax has seen a dramatic increase, with expenses growing by over 760% from 2014 to 2023. This surge reflects Dynavax's aggressive expansion and investment in marketing and administrative capabilities. While Merck's expenses are nearly 100 times larger than Dynavax's, the latter's rapid growth highlights its evolving market strategy. Understanding these trends offers valuable insights into each company's operational focus and strategic priorities.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation